Advertisement

A survey among hospital specialists and pharmacists about biosimilars

      Biological medicines are essential for many acute and chronic conditions [
      • Mellstedt H.
      Clinical considerations for biosimilar antibodies.
      ]. A biosimilar is a version similar to an authorized original biological product with clinical comparability that must be demonstrated in terms of quality, biological activity, safety and efficacy [
      GaBI online — use of biosimilars in Europe differs across countries.
      ]. The consumption of biosimilar medicines differs widely among European countries. Germany has the highest use of biosimilars in Europe, with around 50% volume uptake. Despite initial resistance, Italy and Spain are now catching up and the uptake of biosimilars is increasing [ ], but concerns about efficacy, safety and interchangeability with reference products are frequently expressed by specialists and position papers [
      • Fiorino G.
      • Girolomoni G.
      • Lapadula G.
      • et al.
      The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
      ,
      • Thill M.
      New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mellstedt H.
        Clinical considerations for biosimilar antibodies.
        EJC Suppl. 2013 Dec; 11: 1-11
      1. GaBI online — use of biosimilars in Europe differs across countries.
        (Available from:)
        • European Medicines Agency
        Scientific guidelines on biosimilar medicines.
        ([Accessed on May, 2016])
        • Fiorino G.
        • Girolomoni G.
        • Lapadula G.
        • et al.
        The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
        Autoimmun Rev. 2014 Jul; 13: 751-755
        • Thill M.
        New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
        Expert Rev Anticancer Ther. 2015 Mar; 15: 331-338
        • Fodmark C.E.
        • Lilja K.
        • Woehling H.
        • et al.
        Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden.
        Biol Ther. 2013; 3: 35-43
        • Romer T.
        • Zabransky M.
        • Walczak M.
        • et al.
        Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data.
        Biol Ther. 2011 Dec 16; 1: 5
        • Finnish Medicines Agency
        Are biosimilars interchangeable?.
        ([Accessed on May 20, 2016])
        • Park W.
        • Yoo D.H.
        • Miranda P.
        • et al.
        Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
        Ann Rheum Dis. 2016 Apr 26; ([pii: annrheumdis-2015-208783])
        • Yoo D.H.
        • Prodanovic N.
        • Jaworski J.
        • et al.
        Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
        Ann Rheum Dis. 2016; 29 ([pii: annrheumdis-2015-208786])